M. T. De-boer, M. C. Christensen, M. Asmussen, C. S. Van-der-hilst, H. Hendriks et al., The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation, Anesth Analg. janv, vol.106, issue.1, pp.32-44, 2008.

A. Charles, A. A. Shaikh, M. Walters, S. Huehl, and R. Pomerantz, Blood transfusion is an independent predictor of mortality after blunt trauma, Am Surg. janv, vol.73, issue.1, pp.1-5, 2007.

J. Pillonel, L. Marrec, N. Girault, A. David, D. Laperche et al., Epidemiological surveillance of blood donors and residual risk of blood-borne infections in France, 2001.

, Transfus Clin Biol. juill, vol.12, issue.3, pp.239-285, 2005.

L. Nguyen and Y. Ozier, Risques transfusionnels

, 056X, vol.6

. Disponible,

P. Perez, L. R. Salmi, G. Folléa, J. L. Schmit, B. De-barbeyrac et al., Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM CaseControl Study, Transfusion. juill, vol.41, issue.7, pp.862-72, 2001.

A. Lienhart, Y. Auroy, F. Péquignot, D. Benhamou, J. Warszawski et al., Survey of anesthesia-related mortality in France, Anesthesiology. déc, vol.105, issue.6, pp.1087-97, 2006.

N. Rosencher, H. Kerkkamp, G. Macheras, L. M. Munuera, G. Menichella et al., Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe, Transfusion. avr, vol.43, issue.4, pp.459-69, 2003.

D. A. Henry, P. A. Carless, A. J. Moxey, D. O'connell, B. J. Stokes et al., Antifibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev, p.1886, 2007.

L. G. Glance, A. W. Dick, D. B. Mukamel, F. J. Fleming, R. A. Zollo et al., Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery, Anesthesiology. févr, vol.114, issue.2, pp.283-92, 2011.

J. D. Douketis, A. C. Spyropoulos, F. A. Spencer, M. Mayr, A. K. Jaffer et al., Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines, Chest. févr, vol.141, issue.2, pp.326-350, 2012.

J. D. Douketis, J. S. Healey, M. Brueckmann, J. W. Eikelboom, M. D. Ezekowitz et al., Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure

, Thromb Haemost. mars, vol.113, issue.3, pp.625-657, 2015.

D. R. Spahn, Anemia and patient blood management in hip and knee surgery: a systematic review of the literature, Anesthesiology. août, vol.113, issue.2, pp.482-95, 2010.

A. Greinacher, K. Fendrich, U. Alpen, and W. Hoffmann, Impact of demographic changes on the blood supply: Mecklenburg-West Pomerania as a model region for, Europe. Transfusion. mars, vol.47, issue.3, pp.395-401, 2007.

J. Heeringa, D. Van-der-kuip, A. Hofman, J. A. Kors, G. Van-herpen et al.,

, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, Eur Heart J. avr, vol.27, issue.8, pp.949-53, 2006.

V. Fuster, L. E. Rydén, D. S. Cannom, H. J. Crijns, A. B. Curtis et al., , 2011.

A. Hrs, , 2006.

, Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, J Am Coll Cardiol. 15 mars, vol.57, issue.11, pp.101-98, 2011.

R. B. Schnabel, X. Yin, P. Gona, M. G. Larson, A. S. Beiser et al., 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, Lancet. 11 juill, vol.386, issue.9989, pp.154-62, 2015.

M. Zoni-berisso, F. Lercari, T. Carazza, and S. Domenicucci, Epidemiology of atrial fibrillation: European perspective, Clin Epidemiol, vol.6, pp.213-233, 2014.

B. P. Krijthe, A. Kunst, E. J. Benjamin, G. Lip, O. H. Franco et al., Projections on the number of individuals with atrial fibrillation in the European Union, Eur Heart J. sept, vol.34, issue.35, pp.2746-51, 2000.

D. Kotecha, J. Holmes, H. Krum, D. G. Altman, L. Manzano et al., Efficacy of ? blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis, Lancet. 20 déc, vol.384, issue.9961, pp.2235-2278, 2014.

S. Stewart, C. L. Hart, D. J. Hole, and J. Mcmurray, A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study

, Am J Med, vol.113, issue.5, pp.359-64, 2002.

C. Surgery, A. J. Camm, P. Kirchhof, G. Lip, and U. Schotten, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), European Heart Rhythm Association, European Association for, vol.31, pp.2369-429, 2010.

C. T. Ruff, R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet. 15 mars, vol.383, issue.9921, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

A. Sm, A. Lapointe, N. M. Chatterjee, R. Crowley, M. J. Dupre et al., Rate-and rhythm-control therapies in patients with atrial fibrillation: a systematic review, Ann Intern Med. 3 juin, vol.160, issue.11, pp.760-73, 2014.

L. Anticoagulants-en-france, Etudes et surveillance-ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2018.

. Disponible,

P. Albaladejo, F. Bonhomme, N. Blais, J. Collet, D. Faraoni et al., Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on
URL : https://hal.archives-ouvertes.fr/hal-01809407

, Anaesth Crit Care Pain Med. févr, vol.36, issue.1, pp.73-79, 2015.

H. Autorité-de-santé, Good management practices for oral anticoagulant overdose, situations of hemorrhagic risk and hemorrhagic events in patients taking oral anticoagulants in the ambulatory and hospital setting, 2008.

, J Mal Vasc. déc, vol.33, issue.4-5, pp.202-215, 2008.

J. P. Patel and R. Arya, The current status of bridging anticoagulation, Br J Haematol. mars, vol.164, issue.5, pp.619-648, 2014.

P. Gallego, S. Apostolakis, and G. Lip, Bridging evidence-based practice and practicebased evidence in periprocedural anticoagulation, Circulation. 25 sept, vol.126, issue.13, pp.1573-1579, 2012.

, Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation, BRIDGE Study Investigators, vol.125, pp.496-504, 2012.

J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos et al., The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest. juin, vol.133, issue.6, pp.299-339, 2008.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, issue.38, pp.2893-962, 2016.

J. D. Douketis, J. A. Johnson, and A. G. Turpie, Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen, Arch Intern Med. 28 juin, vol.164, issue.12, pp.1319-1345, 2004.

A. S. Dunn, A. C. Spyropoulos, and A. Turpie, Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT), J Thromb Haemost, vol.5, issue.11, pp.2211-2219, 2007.

A. C. Spyropoulos, A. Turpie, A. S. Dunn, J. Spandorfer, J. Douketis et al., Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry, J Thromb Haemost. juin, vol.4, issue.6, pp.1246-52, 2006.

D. Faraoni, J. H. Levy, P. Albaladejo, C. Samama, and G. , Intérêt en Hémostase Périopératoire. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants, Crit Care. 29 avr, vol.19, p.203, 2015.

J. D. Douketis, A. C. Spyropoulos, S. Kaatz, R. C. Becker, J. A. Caprini et al.,

, Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation, N Engl J Med. 27 août, vol.373, issue.9, pp.823-856, 2015.

J. Beyer-westendorf, V. Gelbricht, K. Förster, F. Ebertz, C. Köhler et al., Periinterventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry, Eur Heart J. 21 juill, vol.35, issue.28, pp.1888-96, 2014.

D. Siegal, J. Yudin, S. Kaatz, J. D. Douketis, W. Lim et al., Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates, Circulation. 25 sept, vol.126, issue.13, pp.1630-1639, 2012.

B. A. Steinberg, E. D. Peterson, S. Kim, L. Thomas, B. J. Gersh et al., Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), Circulation. 3 févr, vol.131, issue.5, pp.488-94, 2015.

L. Forsetlund, A. Bjørndal, A. Rashidian, G. Jamtvedt, M. A. O'brien et al., Continuing education meetings and workshops: effects on professional practice and health care outcomes, Cochrane Database Syst Rev. 15 avr, issue.2, p.3030, 2009.

A. Giguère, F. Légaré, J. Grimshaw, S. Turcotte, M. Fiander et al.,

, Cochrane Database Syst Rev, vol.10, p.4398, 2012.

R. Grol and M. Wensing, What drives change? Barriers to and incentives for achieving evidence-based practice, Med J Aust. 15 mars, vol.180, issue.6, pp.57-60, 2004.

D. S. Likosky, D. C. Fitzgerald, R. C. Groom, D. K. Jones, R. A. Baker et al., Effect of the perioperative blood transfusion and blood conservation in cardiac surgery clinical practice guidelines of the Society of Thoracic Surgeons and the Society of

, Cardiovascular Anesthesiologists upon clinical practices, Anesth Analg. août, vol.111, issue.2, pp.316-339, 2010.

A. Steib, P. Mertes, E. Marret, P. Albaladejo, and J. Fusciardi, Compliance with guidelines for the perioperative management of vitamin K antagonists, Thromb Res. juin, vol.133, issue.6, pp.1056-60, 2014.

M. J. Perrin, B. Z. Vezi, A. C. Ha, A. Keren, P. B. Nery et al., Anticoagulation bridging around device surgery: compliance with guidelines, Pacing Clin Electrophysiol. déc, vol.35, issue.12, pp.1480-1486, 2012.

W. E. Wysokinski and R. D. Mcbane, Periprocedural bridging management of anticoagulation, Circulation. 24 juill, vol.126, issue.4, pp.486-90, 2012.

A. C. Spyropoulos, Pro: « Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery, Thromb Haemost. août, vol.108, issue.2, pp.213-219, 2012.

S. Staender and R. P. Mahajan, Anesthesia and patient safety: have we reached our limits?, Curr Opin Anaesthesiol. juin, vol.24, issue.3, pp.349-53, 2011.

A. Smith and P. Alderson, Guidelines in anaesthesia: support or constraint?, Br J Anaesth. juill, vol.109, issue.1, pp.1-4, 2012.

T. Steinert,

, Psychiatr Prax. juill, vol.36, issue.5, pp.238-280, 2009.

J. S. Alpert, Why are we ignoring guideline recommendations?, Am J Med. févr, vol.123, issue.2, pp.97-105, 2010.

, Annexes Annexe 1. Risques hémorragiques des actes invasifs et chirurgicaux

. Elevé, Risque de saignement majeur à 2 jours 2%-4%

, ? Remplacement valvulaire cardiaque ? Pontage coronarien ? Cure d'anévrisme de l'aorte abdominale ? Neurochirurgie, chirurgie urologique

?. Polypectomie, chirurgie des varices, sphinctérotomie biliaire, dilatation

I. Faible, Risque de saignement faible à 2 jours 0%-2%) : ? Cholécystectomie ? Hystérectomie par voie abdominale ? Endoscopie gastro intestinale +/-biopsie, stent biliaire/pancréatique sans sphinctérotomie échoendoscopie sans ponction biopsie

. Biopsie, Il s'agit de patient homme ou femme de moins de 65 ans avec FA idiopathique et sans facteur de risque

, ? Score 1 : un traitement anticoagulant oral par un AVK (INR 2-3) ou un inhibiteur direct de la thrombine (dabigatran); ou un inhibiteur du Facteur Xa oral (ex. rivaroxaban,apixaban) doit être envisagé, en se basant sur une évaluation du risque hémorragique

, ? Score ? 2 : anticoagulation par AVK (INR entre 2 et 3) ou dabigatran ou les anti Xa (rivaroxaban, apixaban) sauf contre-indication (classe I, niveau A)